CGEM
NASDAQ
$18.06
Cullinan Oncology Inc (CGEM)
Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company is headquartered in Cambridge, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $31.55 (+74.70%)
Market Cap
$1.10B
FCF 5Y CAGR
+46.72%
Free Cash Flow Yield
-16.31%
Beta (5Y)
1.05
Price Chart
Valuation
Market Cap$1.10B
Forward P/E6.74
P/S25.86
P/B2.98
Profitability
Gross Profit (TTM)$19M
EBITDA-$240M
Profit Margin-0.4%
Operating Margin7.2%
EPS-$3.69
Financial Health
Free Cash Flow Yield-16.31%
Growth & Risk
FCF 5Y CAGR+46.72%
Beta (5Y)1.05
Sharpe Ratio1.35